SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ore Pharmaceuticals Inc.
An SI Board Since January 2008
Posts SubjectMarks Bans Symbol
50 1 0 ORXE
Emcee:  Mike McFarland Type:  Moderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
25Ore Pharmaceuticals Announces Completion of Multiple Ascending Dose GL1001 CliniMike McFarland12/5/2008
24financial results for the third quarter ended September 30, 2008 phx.corporate-iMike McFarland10/31/2008
23Ore Pharmaceuticals Begins Clinical Trial of GL1001 phx.corporate-ir.net CompanMike McFarland10/1/2008
22Ore sells DioGenix to Nerveda, Larry Tiffany resigns orepharma.comMike McFarland9/23/2008
21Ore Pharmaceuticals Acquires Rights to Develop a Second Drug Candidate from RochMike McFarland8/7/2008
20Ore Pharmaceuticals Reports Second Quarter 2008 Financial Results phx.corporate-Mike McFarland8/1/2008
19(I'll listen to the archive when I get a chance over the weekend--I'll bMike McFarland7/31/2008
18Ore Pharmaceuticals Acquires Repositioned Clinical-Stage Drug Candidate from RocMike McFarland7/31/2008
17Ore files IND for GL1001 phx.corporate-ir.netMike McFarland7/1/2008
16Ore Pharmaceuticals Focuses Resources on Development of Repositioned Compounds Mike McFarland6/16/2008
15On June 10, 2008, Ore Pharmaceuticals Inc. (the "Company") received noMike McFarland6/12/2008
14DioGenix Discovers Gene Sets Which Correlate to Multiple Sclerosis Will ConductMike McFarland6/10/2008
13one-for-five reverse stock split, shareholders will be ORXED after the close todMike McFarland5/23/2008
12Ore Pharmaceuticals Presentation – Rodman & Renshaw 5th Annual Global HealthMike McFarland5/19/2008
11Don't know why I even bother to post, but the quarterly report is here orephMike McFarland5/8/2008
10So, this might be the last post for me on a thread that I probably should not haMike McFarland4/17/2008
9I've never stumbled on this blog Omics! Omics! before now <i>I think yMike McFarland4/2/2008
8<i>WHEREAS, following the sale of the Company's Genomics Division, MilMike McFarland3/15/2008
7<i>ORXE buys the Miller shares for a little under $3.3M (and he resigns) Steve Lokness3/15/2008
6ORXE buys the Miller shares for a little under $3.3M (and he resigns) yahoo.braMike McFarland3/14/2008
5shares available--ask: 0.54 x 72700Mike McFarland3/14/2008
4This family trust or whatever it is looks like it has been buying all the way doMike McFarland3/3/2008
3$32.8 million on 12/31/07 and <i>Not including the impact of the sale of tMike McFarland2/22/2008
2RENAISSANCE TECHNOLOGIES LLC SC 13G 2/13/2008 and there is one there from a weeMike McFarland2/13/2008
1ORXE has dropped about twenty cents a share, or about 25% over the past three orMike McFarland1/29/2008
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News